Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

a of PL-3994 and a new peptide drug candidate for sexual dysfunction.

CASH POSITIONPalatin's cash and cash equivalents were $14.9 million as of September 30, 2011, compared to $18.9 million at June 30, 2011, with current liabilities of $1.7 million as of September 30, 2011 compared to $2.8 million as of June 30, 2011.

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on November 15, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-256-1007 (domestic) or 1-913-312-1466 (international), pass code 3249586. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 3249586.  The webcast and telephone replay will be available through November 22, 2011.

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.  

Forward-looking Statements Statements
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Buffalo, New York (PRWEB) March 27, 2015 ... of the 2015 application period for 43North - the ... cash prizes, including a grand prize of $1 million, ... attracts entrepreneurs from around the world to compete for ... into funded enterprises in the Western New York region. ...
(Date:3/26/2015)... Bruno, CA (PRWEB) March 26, 2015 ... (CRO), announced today several management and executive appointments ... of Chief Financial Officer (CFO) and member of the ... President of Business Operations, and Sue Dowden will assume ... Taricco, co-founder and current Chief Operations Officer (COO), has ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound ... Designing Gig LLC to provide website design, development, and ... this alliance with Designing Gig represents a pivotal moment ... comprehensive, end-to-end, digital solution for our clients, which now ... Miller, president of The Market Element. “For small and ...
(Date:3/26/2015)... LEXINGTON, Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ... announced a three-year, broad research collaboration for rare ... and develop novel therapies to treat rare diseases ... and commercialization capabilities with Cincinnati Children,s research expertise. ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... pattern has led materials scientists at the National Institute ... Solid State Physics in Russia to an unexpected findingthe ... used in data storage. Their recently reported findings* may ... of future ultra-high density data storage devices. The ...
... 1 Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced ... as Directors. , , "We are pleased to welcome ... to us as we move into our next stage of development," ... Ms. Wilson has been a principal of Wilson Boyles and Company, ...
... Inc., a subsidiary of Eisai Corporation of North America, ... to express and develop therapeutic monoclonal antibodies for the ... disease. , , Under the terms of the ... (SEP(TM)) technology and its expertise to produce and develop ...
Cached Biology Technology:Unexpectedly long-range effects in advanced magnetic devices 2Biocept, Inc. Announces Two New Director Appointments 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
(Date:3/5/2015)... PAULO , March 5, 2015 In ... 41 percent of companies already using these solutions and 42 ... 2015. Of the latter, approximately 25 percent of the companies ... While the majority of companies in the region ... anticipated that the hybrid model will command significant attention in ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... Chicago, IL The American Society of Pediatric Otolaryngology (ASPO) ... field of pediatric otolaryngology during their annual meeting, April ... awards will be presented during a banquet reception on ... & Towers. Two prestigious groups of awards will ...
... , Hamilton, ON (April 24, 2011) An over-the-counter ... antibiotic used to treat bacterial infections, could one day ... Researchers at McMaster University have discovered this ... a frequent complication of those with cystic fibrosis. Cystic ...
... RICHLAND, Wash. -- Atmospheric scientists trying to pin down ... warm the earth have found that it depends on ... will help researchers improve how they portray clouds in ... scattered by clouds the reason why beachgoers can ...
Cached Biology News:Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients 2Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 2Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 3Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 4
... and high speed homogeneous assay for the ... for screening of inhibitors in a high-throughput ... on a fluorescence superquenching technology that does ... universal platform provides flexibility for assaying any ...
... The HDA-GT12 Genetic Analyzer is ... multiple applications in one instrument platform. It ... in one step, thus significantly improving the ... to high-throughput laboratories . Benefits of ...
...
...
Biology Products: